45% of Australians will suffer from a mental illness in their lifetime…

What are we going to do about it?

A new paradigm for mental health

Mind Medicine Australia is a charity that enables the development of regulatory-approved and research-backed psychedelic-assisted psychotherapy for the treatment of mental ill-health in Australia.

Mind Medicine Australia is seeking to establish safe and effective psychedelic-assisted treatments for mental illness in Australia. As a registered charity (DGR-1 status), we are supporting clinical research and working towards regulatory-approved and evidence-based psychedelic-assisted therapies. We operate as a nexus between medical practitioners, academia, government, regulatory bodies, philanthropists, and other partners.

Mind Medicine Australia is focused specifically on the clinical application of medicinal psilocybin and medicinal MDMA for certain mental illnesses. We do not advocate for recreational use of psychedelics, MDMA, or any other prohibited substances, nor do we advocate for any changes to the law with respect to recreational use. Our focus is wholly clinical.


About 15% of the world’s population (1.1 billion people) currently have a mental illness. In Australia, mental illness is the leading cause of non-fatal disease burden, and the third leading cause of total disease burden, and nearly half of all Australians will experience a mental illness at some point in their lives. If you are not affected, someone dear to you is likely to be. In addition, the direct cost of mental illness in Australia is at least $28.6 billion annually. While certain treatments have helped a minority of sufferers in a sustainable way, the vast global effort to understand and treat mental illness over the past many decades has yielded inadequate outcomes.

a new paradigm

The past decade has seen renewed interest and progress in psychedelic-assisted therapies. In rigorous and well-controlled clinical trials, psychedelic-assisted psychotherapy (using classical psychedelics such as psilocybin, and related compounds such as MDMA) has produced remarkable clinical outcomes for individuals suffering with addiction, depression, end-of-life distress, and Post Traumatic Stress Disorder. Preliminary and currently active trials are investigating additional applications, for example within obsessive compulsive disorder and autism. About one hundred psychedelic and MDMA research trials have recently been completed or are currently active. Results from clinical trials have been so compelling that the US Food and Drug Administration (FDA) recently designated psilocybin- and MDMA-assisted psychotherapies as ‘breakthrough therapies’, expediting their research and development.


For largely political reasons, psychedelic research and therapy has been substantially constrained since 1970. However, the past decade has seen a resurgence in psychedelic research, alongside a decline in associated stigmas, and an increase in interest within the general population, the scientific community, and politics. While over one hundred psychedelic trials have been conducted over the past decade, Australia’s first clinical trial – run by PRISM and St Vincent’s Hospital, and co-sponsored by Mind Medicine Australia – is only just kicking off in 2019. We are seeing the emergence of a different paradigm in mental health treatment, with early yet mounting evidence indicating impressive outcomes. This is an historic moment in mental health research and treatment. It is time for Australia to join this exploration.

Launch Event of Mind Medicine Australia

We celebrated the launch of Mind Medicine Australia on 13th February 2019 with a  community of Australian changemakers at The University of Melbourne. 

University of Melbourne Logo

Please watch and share videos from the launch of Mind Medicine Australia.

Launch Highlights

Professor David Nutt’s International Keynote lecture titled ‘Psychedelic therapy: Changing the paradigm for mental health

Launch Address by Peter Hunt AM and Tania de Jong AM

Close Menu